{
  "id": 12925038,
  "title": "Nvidia-backed Iambic Therapeutics launches IPO as biotechs buck market gloom",
  "url": "https://urgent.news/2026/10/08/nvidia-backed-iambic-therapeutics-launches-ipo-as-biotechs-buck",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-08T18:18:28.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/stock-market-news/nvidiabacked-iambic-therapeutics-launches-ipo-as-biotechs-buck-market-gloom-4939603"
  },
  "original_language": "en",
  "account": "Nvidia-backed Iambic Therapeutics, leveraging artificial intelligence for drug development, is set to launch its IPO in the United States, aiming to raise up to $159.4 million. This biotech sector offering reflects the sector's emergence as a positive indicator amidst a generally sluggish market. Iambic Therapeutics, valued at up to $805.8 million following the IPO, would be positioned within the higher range of its indicated price. The biotech company's prospects are bolstered by the increasing investment interest in AI-driven drug discovery, a field where AI's contribution to drug candidate identification and development acceleration is evident. Iambic Therapeutics is projecting the sale of approximately 9.38 million shares priced between $15 and $17 each. Major investment firms ARK Investment Management and Duquesne Family Office have shown interest in purchasing shares totaling $60 million. Established in 2019 as Entos, Iambic Therapeutics is currently advancing a pipeline of drug candidates developed through its AI platform, focusing on the treatment of solid tumors. The company has strategic partnerships with major pharmaceutical firms such as AbbVie and Takeda Pharmaceutical. Iambic Therapeutics is positioned as a clinical-stage biotech company utilizing AI-enhanced drug discovery, rather than a pure AI enterprise. According to Kat Liu, an IPOX vice president, the company's valuation hinges primarily on the strength of its pipeline and the likelihood of eventual approval and commercialization. A successful listing could differentiate Iambic Therapeutics in a fall IPO market characterized by delays due to rising Treasury yields and market volatility, along with heightened caution among investors. The absence of enthusiasm towards a potential AI trade overheating and ongoing geopolitical tensions has further stifled investor interest, rendering biotech among the few sectors attracting attention. Iambic Therapeutics plans to trade on the Nasdaq under the ticker symbol IAM following its IPO. Lead underwriters for the offering include J.P. Morgan, Jefferies, BofA Securities, and Citigroup.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}